anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Cefixime trihydrate 100 mg/5 mL dry syrup was dissolved by 20 mL of water split in 2 portions. Then the drug was shaken well for at least 30 seconds at each addition of water.
FIELD: medicine. ^ SUBSTANCE: invention concerns the compositions including antigens Chlamydia trachomatis (CT), and to their application in vaccines. Concrete combinations of antigens as a part of compositions can be chosen from the first group of antigens PepA, LcrE, ArtJ, DnaK and CT398, and the second group of antigens PepA, LcrE, ArtJ, DnaK, CT398, an OmpH-like antigen, L7/L12, OmcA, AtoS, CT547, Eno, HtrA and MurG. The invention also concerns the application of combinations of adjuvants in a combination of an antigen or antigens, associated with disease transferable by sexual way, such as antigens Chlamydia trachomatis. Preferable combinations of adjuvants include mineral salts, such as aluminium salts, and the oligonucleotides including CpG-motive. ^ EFFECT: combinations of antigens CT under the invention are protective concerning infection with chlamydias, are capable to induce the immune humoral response, at least, in respect of TH1-cell profiles which can quickly react to influence of chlamydias. ^ 23 cl, 29 dwg, 4 tbl, 5 ex
Highly cross-linked polyethylene (HXLPE) has improved polyethylene (PE) wear rates while decreasing osteolysis and aseptic loosening. However, concerns exist regarding the risk of mechanical failure with thin HXLPE liners in total hip arthroplasty (THA). Our purpose was to evaluate long-term outcomes and PE wear rates in primary THAs pairing large femoral heads with small acetabular components and thin HXLPE liners. We retrospectively reviewed 29 patients who underwent 33 primary THAs using large femoral heads (32 or 36 mm) with small acetabular components (48 or 50 mm) and thin HXLPE liners (3.9 or 5.9 mm) at minimum 10-year follow-up. PE liner wear was measured using a validated radiographic technique. Mean age was 66 years, 97% of the patients were women, and mean body mass index was 26.3 kg/m2. Thirty hips (90.9%) had ceramic femoral heads, and 13 hips (39%) had 36-mm femoral heads with 3.9-mm HXLPE liners. All cases used a neutral PE design. Mean linear wear rate and volumetric wear rate were 0.04 mm/year and 39.6 mm3/year, respectively, at mean 10.9-year follow-up. There were no instances of liner fracture, liner dissociation, or revision. Mean Hip disability and Osteoarthritis Outcome Score for Joint Replacement (HOOS, JR) was 92.1. In the largest long-term study of primary THAs using large femoral heads with small acetabular components and thin HXLPE liners, we found low linear and volumetric wear rates and no cases of liner mechanical failures. Thin HXLPE liners are a safe and viable option for THA surgeons. [Orthopedics. 2024;47(2):118-122.].
BACKGROUND: Inflammation and obesity have been widely recognized to play a key role in Diabetes mellitus (DM), and there exists a complex interplay between them. We aimed to clarify the relationship between inflammation and DM, as well as the mediating role of obesity in the relationship.
METHODS: Based on the National Health and Nutrition Examination Survey (NHANES) 2005-2018. Univariate analyses of continuous and categorical variables were performed using t-test, linear regression, and χ2 test, respectively. Logistic regression was used to analyze the relationship between Systemic Immune-Inflammatory Index (SII) or natural logarithm (Ln)-SII and DM in three different models. Mediation analysis was used to determine whether four obesity indicators, including body mass index (BMI), waist circumference (WC), visceral adiposity index (VAI) and lipid accumulation product index (LAP), mediated the relationship between SII and DM.
RESULTS: A total of 9,301 participants were included, and the levels of SII and obesity indicators (BMI, WC, LAP, and VAI) were higher in individuals with DM (p < 0.001). In all three models, SII and Ln-SII demonstrated a positive correlation with the risk of DM and a significant dose-response relationship was found (p-trend <0.05). Furthermore, BMI and WC were associated with SII and the risk of DM in all three models (p < 0.001). Mediation analysis showed that BMI and WC mediated the relationship between SII with DM, as well as Ln-SII and DM, with respective mediation proportions of 9.34% and 12.14% for SII and 10.23% and 13.67% for Ln-SII (p < 0.001).
CONCLUSION: Our findings suggest that increased SII levels were associated with a higher risk of DM, and BMI and WC played a critical mediating role in the relationship between SII and DM.
Scaffold peptides and methods of making and using same. The scaffold peptides have a general structure from the N-terminus to the C-terminus, AH 1 -linker-AH 2 . AH 1  and AH 2  each comprise an alpha helical structure and may fold against each other about the linker to form a bi-helical structure. The scaffold peptide includes alternating polar and non-polar regions. The non-polar regions of the scaffold peptide interact with the hydrophobic regions of the proteins to solubilize same in aqueous solutions without the presence of detergent. In some embodiments, the scaffold peptides are used for hydrophobic protein purification, isolation and/or stabilization.
Patients undergo sham training on days 1-14. Patients then receive nicotine patches for up to 8 weeks.
PURPOSE:To obtain an oily solid material, remarkably improved in strengths, stability such as oil separation resistance and dispersibility of pigments and useful as an oily base of a cosmetic, a medicine, a crayon, etc., by adding a specific modified polyethylene wax to a liquid oil and/or a solid oil. CONSTITUTION:This oily solid material is obtained by adding a modified polyethylene wax expressed by formula I, II or III [R<1> is a 1-7C saturated hydrocarbon; (n) and (m) are each a number providing an average value of 10-1000; (x) is 0.9-1; R<2> and R<3> are each H, a 1-18C aliphatic hydrocarbon or an aromatic hydrocarbon, with the proviso that R<2> and R<3> are not simultaneously H] to a liquid oil and/or a solid oil. The compound expressed by formula I is prepared by carrying out the living polymerization of, e.g. ethylene and then performing the oxidation with oxygen or reacting formaldehyde and further carrying out the neutralizing treatment with an acid. The compound expressed by formula II is obtained by carrying out the living polymerization of, e.g. ethylene, reacting a carbonyl compound expressed by formula IV therewith and further performing the neutralizing treatment with the acid. The compound expressed by formula III is prepared by carrying out the living polymerization of, e.g. ethylene, reacting a formic acid ester therewith and further performing the neutralizing treatment with the acid.
Gastric cancer is among the most common malignant tumors nationwide with high morbidity and mortality. Attributing to its insidious onset and rapid progress, 70% of patients with gastric cancer were initially diagnosed at an advanced stage. In advanced gastric cancer, systemic treatment based on chemotherapy drugs, targeted drugs, and immune checkpoint inhibitors remains the main regimens. Among current standard treatment regimens, though HER2-positive and MSI-H/dMMR statuses indicate the treatment efficacy of trastuzumab and immune checkpoint inhibitors, there is still lack of robust biomarkers for predicting treatment efficacy. Tumor microenvironment as pivotal components of solid tumor, significantly influences therapeutic response and clinical outcome. The study is a multi-center, observational study to evaluate the relationship between standard treatment efficacy and the tumor microenvironment in advanced gastric cancer. In addition, the study comprehensively evaluated the landscape of the tumor microenvironment characteristics of gastric cancer, and aimed at establishing robust biomarkers for predicting prognosis and treatment efficacy to finetune treatment strategies. Eligible subjects were selected according to the inclusion criteria and exclusion criteria. After successful screening, the patients were treated following the clinical guidelines and the actual conditions. The residual tissue samples of the primary tumor or metastatic foci were collected to conduct the tumor microenvironment detection analysis.
NEW MATERIAL:An azole propylene glycol derivative shown by the formula I (Q is imidazolyl, or triazolyl; X<1>, X<2>, Y<1>, and Y<2> are H, halogen, alkyl, trifluoromethyl, alkoxy, or nitro, respectively) or its acid addition salt. EXAMPLE:1,2-Bis(2,4-dichlorophenyl)-3-(1H-imidazol-1-yl)propylene glycol. USE:Showing improved antifungal action, useful as a drug or a drug for animals. Effective as an antifungal agent especially for internal use and injection. PREPARATION:A raw material compound shown by the formula II is subjected to oxirane formation reaction, to give an ethylene oxide shown by the formula III. This compound shown by the formula III is then reacted with 1H-imidazole, etc. to give a ketol shown by the formula IV, the compound shown by the formula IV is reduced, to give a compound shown by the formula I .
The participants in this arm will receive Iron-Folic Acid (IFA) supplements. The recommended doses of iron-folic acid are 30-60 mg of elemental iron and 400 µg of folic acid combined. In this trial, we will use ferrous sulfate with 30 mg of iron and 400 µg of folic acid in the form of capsule. The supplementation will be given to the study subjects twice a week for 17 weeks.
For best results, use tc99m from a generator eluted within 24 hours. The eluate should be used within 2 hours of elution.

Reconstitution Instructions:

  1. Snap off the plastic lid and place in appropriate lead shielding. Wipe the septum with 70% isopropyl alcohol and allow it to dry
  2. Using a 10 mL syringe, draw up 15-80 mCi of tc99m. Dilute this to 7.5 mL with sterile preservative free saline and inject into the vial, being sure to withdraw an equal amount of gas from the vial to neutralize pressure.
  3. Rock and invert the shielded vial for 10 seconds. Wait 2 minutes before adding stabilizer to allow for tagging.


  * Add stabilizer to extend the length of time before use
  * If no stabilizer is added, use the vial within 30 minutes.



Stabilizer Use:

Cobalt Chloride as a stabilizer: Wait 2 minutes after adding tc99m. Then add 3 mL of Cobalt Chloride to tc99m HMPAO. Solution is clear but slightly tan, which is normal. Swirl contents to mix and inspect solution for particulates. Draw 0.1 mL for a quality control sample. Solution is stable for 6 hours. This stabilizer can be used in WBC labeling

Methylene blue and Phosphate buffer as a stabilizer: Add 0.5 mL of 1% methylene blue to 4.5 mL of phosphate buffer solution. Swirl contents to mix then draw 3 mL and add to HMPAO within 2 minutes of mixing tc99m. Filter the final solution using a 0.22µm filter into an empty sterile vial. Draw 0.1 mL sample for quality control. Radiochemical purity must be 80% or higher. Solution is stable for 4 hours. This stabilizer is not recommended for use in WBC labeling
The metacarpophalangeal joint is vital for hand function. Cartilage loss of the joint is central to the development of joint failure in arthritis. Although various treatments have been proposed, the management remains a challenging problem.Previous anatomical studies have shown that, at the base of the metacarpal, there were nutrient arteries inserting into the dorsum of the metacarpal. The nutrient arteries arise from the distal and middle dorsal carpal arches that run distally to the first to fourth dorsal metacarpal arteries (DMAs. These studies prompt us to use a reverse vascularized cartilage and bone graft based on the DMA. The metacarpal consists of a widened proximal base. The joint surface to the capitate is convex anteriorly and dorsally concave, where it extends to the styloid process on the dorsolateral aspect of the metacarpal base. The unique contour stimulates our imagination and creativity to use a portion of the joint surface for reconstruction of metacarpophalangeal joint defects. The purpose of this study is to report the novel technique and to evaluate the effectiveness of the treatment.
PROBLEM TO BE SOLVED: To obtain am antiallergic medicine useful for treating and preventing allergy, particularly allergic diseases I and II by incorporating, as an active ingredient, a tissue inhibitor selected from tissue inhibitors against metalloprotease(TIMPs). SOLUTION: This medicine contains, as an active ingredient, a tissue inhibitor [inhibitor which specifically inhibits the activity of matrix metalloproteases(MMPs)] selected from tissue inhibitors against metalloprotease(TIMPs). It is preferable to administer the medicine to an adult (60 kg) orally at a dose of 0.01 mg-1 g per day, or parenterally, for example, by injection at a dose of 0.001 mg-30 mg per day, or as ointment at a dose of 0.01-100 mg per each application. This medicine is useful particularly for allergy I (e.g. atopic dermatitis, bronchial asthma, and pollen disease) and allergy IV (e.g. allergic contact dermatitis).
<P>PROBLEM TO BE SOLVED: To provide an iron oxide complex for administration to a mammalian subject.  <P>SOLUTION: A composition, and methods of producing and using the composition are provided for an enhanced magnetic resonance imaging agent and a hematinic agent. The agents comprise a carboxyalkylated reduced polysaccharide-coated ultrafine superparamagnetic iron oxide. The method of using carboxymethyl-reduced dextran as a plasma extender is also provided. The invention further provides, as another embodiment, a method for preparing the iron oxide complex coated with a reduced polysaccharide.  <P>COPYRIGHT: (C)2011,JPO&INPIT
Participants received Delamanid 200 mg (4x50 mg tablets), orally, BID along with at least 4 additional anti-TB medications per OBR up to Week 26. Participants were administered OBR as directed by the given investigator based on WHO guidelines and clinical judgment. A participant might have been titrated to Delamanid 200 mg BID after an initial hospitalization of 2 weeks. Participants were grouped according to the longest duration of Delamanid dose administered during the study.
The purpose of this study is to determine the effectiveness of teriparatide (FORTEO), which is human parathyroid hormone 1-34, for increasing bone mass and improving bone structure in adults affected with Osteogenesis Imperfecta (OI). Osteogenesis imperfecta is an inherited disorder of type I collagen, a major component of bones, and is characterized by multiple fractures and deformities. OI affects approximately 1-2 of every 10,000 individuals. Virtually all of the studies of potential treatments for OI have evaluated the effects of medications only on children with OI. There is no cure for osteogenesis imperfecta and there is no established medical therapy for adults with the disorder. There are very limited data concerning the usefulness of parathyroid hormone therapy in OI. An effective anabolic therapy for the treatment of adult patients with OI could be a valuable asset to the affected patients. In this study, the working hypothesis is that individuals affected with OI who are treated with Forteo will experience increased spine and hip bone mineral density and an increase in bone strength. Although Forteo is not expected to change the defect in the collagen produced, but is postulated to increase the quantity of bone formed and improve bone strength.

This will be a placebo controlled, double blinded trial; half the patients will receive Forteo 20 ug/day SQ. Adult patients (age at least 18 yrs) with OI will be enrolled for a treatment duration of 18 months. Blood, urine, and bone density/strength tests will be done during the study to assess efficacy and safety.
Septorhinoplasty is one of the most common esthetic surgeries in the world. The septorhinoplasty is accompanied by insignificant bleeding on the surgical field. Excessive bleeding compromises the surgical field quality and makes more difficult the septorhinoplasty. It is very important to control and minimize excessive bleeding in surgical field by different approaches of anesthesia management. Successful approaches to reduce the excessive bleeding are; controlled hypotension by keeping the mean arterial pressure in the range of 60-70 mmHg, the reverse Trendelenburg position of the patient, administration of adrenaline (injection prior to surgery or packing soaked during surgery), and administration of tranexamic acid, which are applicable methods in many clinical centers.

Cardiac output may vary depending on the autonomic nervous system. The dominance of parasympathetic system effect may cause vasodilation, decrease in blood pressure and cardiac output. This vasodilation may increase bleeding during septorhinoplasty and worsen the surgical field quality. Anesthesia management may provide a clear view for the surgeon and an improved surgical field quality. The effect of carbon dioxide on vascular reactivity deserves an extra attention in septorhinoplasty required bleeding control. The intensity of bleeding in septorhinoplasty is mainly affected by mean arterial pressure and heart rate. At the same time, blood flow can be affected directly by carbon dioxide on the smooth muscular tonus of the arterioles.

After all, it is unknown whether different carbon dioxide pressure levels have a clinically significant effect on bleeding and surgical field quality in septorhinoplasty, especially during controlled hypotension. Therefore, it was aimed to investigate the effect of ventilation strategy with controlled hypocapnia on intraoperative bleeding and surgical field quality for commonly practiced in septorhinoplasty.
Treatment will be undertaken with a ready-to use investigative drug formulation identical to what is in diagnostic use as a contrast medium for MRI. Formulation content: MnDPDP 10 mmol/ml.
Percutaneous nephrolithotomy/nephrolithotripsy (PCNL) is an effective treatment that offers maximal physical removal of large kidney stones. However, despite the minimally invasive nature of the procedure, postoperative pain still remains a significant concern. General anaesthetic (solution given to put the patient to sleep) for the procedure is routinely given, along with a local anaesthetic injection at the operative site (injection of anaesthetic solution to the incision area to reduce the pain after the procedure) and pain pills to reduce the pain even further after surgery. Paravertebral nerve blockade (PVB) is a technique for inserting anesthetic solution into an area near the vertebrae (bony segments that form the spinal column of humans or backbone), and is an effective method for reducing pain in the post operative period from a variety of surgeries.

The investigators expect that the PVB can decrease side effects from opioids (pain medication) and other analgesics used post-operatively. Opioid side effects include nausea, vomiting, urinary retention, constipation, and drowsiness. Other side effects associated with anaesthetic use include peptic ulcer disease and acute renal failure. The investigators also expect that PVB will result in decreased post-operative pain.
We report the cases of 4 patients treated for recurrent meningiomas of various grades. Pretreatment 68 Ga-DOTATOC PET/CT was performed prior to screening for vectorized internal radiotherapy with 177 Lu-DOTATATE or prior external radiotherapy to aid contouring. None of these patients had sufficient uptake to be eligible for 177 Lu-DOTATATE or reliable contouring. Most recurrences were grades II and III, suggesting a loss of physiological somatostatin receptor overexpression in these tumors. Therefore, the benefit of treatment with 177 Lu-DOTATATE in the current indication is questionable. In the absence of a validated systemic treatment, and considering a few case reports, treatment with 177 Lu-PSMA could be investigated as an additional vectorized internal radiotherapy option.
Pergoveris 150 -300 IU start from day 2 of the cycle up to the day of trigger, GnRH antagonist 0,25 mg start from day 7-8 of the cycle up to the day of trigger, final trigger of ovarian stimulation - GnRH-a 0,2 mg, oocyte retrieval 35 hours after trigger, stop period for 5 days, after stop period start Pergoveris 150 - 300 IU start up to the day of trigger, GnRH antagonist 0,25 mg start from day 6 of ovarian stimulation up to the day of trigger, final trigger of ovarian stimulation - GnRH-a 0,2 mg, oocyte retrieval 35 hours after trigger. After oocyte retrieval fertilization will be carried out by IVI or ICSI, the development of embryos will be carried out up to blastocyst stage, then blastocyst vitrification will be performed.
The present invention relates to NF-X1, a novel DNA binding protein which regulates expression of major histocompatibility complex (MHC) class II molecules, and to DNA sequences which encode the protein as well as recombinant expression of the protein. NF-X1 is a newly identified, cysteine-rich polypeptide which interacts sequence-specifically with the conserved X1 box regulatory element found in the proximal promoters of class II MHC genes. A cysteine-rich domain within NF-X1 contains a motif repeated seven times, and this entire region is necessary and sufficient for both sequence specific binding and effector function. The motif is related to but distinct from the previously described metal-binding protein families: LIM domain and RING finger. NFX.1 mRNA is markedly overexpressed late after induction of cells with interferon-gamma, and this overexpression coincides with a reduction in the level of HLA-DRA transcript in these cells. Overexpression of this protein strongly and specifically represses the transcription of the HLA-DRA gene in MHC class II positive cell lines, indicating that the NF-X1 protein is a transcriptional repressor of MHC class II molecules.
The present invention relates to a traditional Chinese medicine composition for treating diabetic heart disease, which takes more than 10 Chinese herbal medicines of platycladi seed, roasted thinleaf milkwort root-bark, crude fossilizid, grassleaf sweelflag rhizome etc. as the raw materials. The present invention has the effects of relieving convulsion, stabilizing mind, nourishing heart and tranquilizing. Based on the differential treatment of the traditional Chinese medicine, the invention is developed by combining the latest scientific research results with the traditional Chinese medicine. The present invention aims at providing the traditional Chinese medicine composition for treating diabetic heart disease. The present invention is characterized by accurate efficacy, safety, convenience, no toxicity or side effects and low price.
New fibrin/antibiotic composite chain consists of antibiotic contg. fibrin globules aligned on a thread which can be absorbed by the human organism. Antiseptic implant for use e.g. following surgery or for antiseptic treatment of body cavities. The product is completely absorbed, so that surgery is not needed for its removal. Antibiotic release is complete within 5-8 days, so that resistance development due to prolonged release of low levels of antibiotic is avoided. The product can be dried, and in dried form it can be stored and despatched without the need for eryogluic packaging. Pref. the fibrin globules consist of human fibrinogen hardened onto the thread by means of thrombin. The choice of antibiotic can be based on an antibiogran; thermal instability of the antibiotic is not a problem, since the thrombin/prothrombin reaction is not exothermic. Antibiotic content can vary within wide limits. The product can be moulded into suitable shapes (e.g. as tablets) using simple metal or plastics moulds or by using conventional tabletting techniques.